Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $131.14, giving the company a market capitalization of 165.95B. It carries a P/E multiple of 20.00 and pays a dividend yield of 2.4%.
On 2026-01-22, Gilead Sciences(GILD) stock moved within a range of $128.40 to $133.10. With shares now at $131.14, the stock is trading +2.1% above its intraday low and -1.5% below the session's peak.
Trading activity shows a volume of 8.55M, compared to an average daily volume of 7.11M.
The stock's 52-week range extends from a low of $91.84 to a high of $133.10.
The stock's 52-week range extends from a low of $91.84 to a high of $133.10.
GILD News
Gilead Sciences (GILD) is back in focus after detailed Phase 3 ASCENT-04/KEYNOTE-D19 results in The New England Journal of Medicine showed that Trodelvy plus Ke...
The company states: “Gilead (GILD) Sciences announced The New England Journal of Medicine published the full results from the positive Phase 3 ASCENT-04/KEYNOTE...
Gilead Sciences (NasdaqGS:GILD) received FDA approval for Yeztugo, a twice-yearly injectable for HIV prevention. The company has started the commercial rollout...